
    
      Participants who were randomized to the GA 40 mg treatment arm in the Double-Blind Period,
      continue that treatment in the Open-Label Extension Period and are referred to as "Early
      Start" participants. Participants randomized to the Placebo arm in the Double-Blind Period
      and switched to GA 40 mg subcutaneous injections three times a week in the Open-Label
      Extension are referred to as "Delayed Start" participants.
    
  